论文部分内容阅读
自1959年Thomas首先对1例大剂量放射疗法后的白血病患者试用人胎肝细胞(FLC)输注液,国内外学者开始了FLC在血液病领域中的临床应用研究,并取得了一定效果,但用FLC治疗肝脏疾患国外很少报告。国内近些年来已开始研究,并取得了不少成功经验,国家重症肝炎攻关组和安徽黄山医学会于1989年7月联合召开了FLC临床应用研讨会。现将人胎肝细胞的临床应用、疗效机理及胎肝细胞溶液制作的质量控制等问题分述如下: 一、临床疗效的探讨 1988年全国传染病与寄生虫病会议上,有多篇关于FLC治疗重肝的报告;归纳有关材料,没有对照组的共治疗92例,存活69例(75％);有对照组的研究,治疗组共35例,存活23例(65.7％),对照组24例存活8例(33.3％),也有人在结合治疗中加用FLC输注,其疗效为73.3％(11/15),优
Since 1959 Thomas first trial of a case of leukemia patients after high-dose radiation therapy of human fetal liver cells (FLC) infusion, domestic and foreign scholars began clinical application of FLC in the field of blood disease, and achieved some results, However, the treatment of liver disease with FLC rarely reported abroad. In recent years, China has started to study and has gained a lot of successful experiences. The National Severe Hepatitis Research Group and Anhui Huangshan Medical Association jointly held the FLC clinical application seminar in July 1989. Now the clinical application of human fetal liver cells, the mechanism of efficacy and fetal liver cell solution quality control and other issues are described below: First, the clinical efficacy of the 1988 National Infectious Diseases and Parasitic Diseases meeting, there are many articles on FLC There were 92 cases (75%) survived in the control group, 35 cases in the control group, 23 cases in the treatment group (65.7%), and 24 cases in the control group Cases of survival in 8 cases (33.3%), but also in combination therapy with FLC infusion, the effect was 73.3% (11/15), excellent